Table: Santen Pharm -Q1 group results (IFRS)
06/08/2024 07:02
Aug 6 (Reuters)-
Santen Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2024 Jun 30, 2023 Mar 31, 2025
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 74.77 72.39 302.00
(+3.3 pct) (+10.5 pct) (+0.0 pct)
Operating 13.16 12.75 44.50
(+3.2 pct) (+53.0 pct) (+15.5 pct)
Pretax 13.45 12.87 45.00
(+4.5 pct) (+41.8 pct) (+50.6 pct)
Net 10.63 10.41
(+2.1 pct) (+56.3 pct)
EPS Basic 29.59 yen 27.93 yen 92.22 yen
EPS Diluted 29.50 yen 27.85 yen
Ann Div 33.00 yen 34.00 yen
-Q2 Div 16.00 yen 17.00 yen
-Q4 Div 17.00 yen 17.00 yen
NOTE - Santen Pharmaceutical Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T